New General Manager for Lilly UK, Ireland and Northern Europe

Laura Steele will lead Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience.

Eli Lilly & Company announced that Laura Steele has been appointed President and General Manager (GM) for UK, Ireland & Northern Europe.

Steele will lead Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience. She brings 18 years’ experience with the company to her new role, and joins from Lilly’s Corporate Business Development division, where she specialized in innovation partnerships, large-scale projects in M&A, investments and joint ventures, to drive growth across the company.

“As we emerge from the COVID-19 pandemic, we must build on what we have learned during this crisis. From accelerating the set-up of new clinical trials to advances in delivering care outside of traditional settings, and combating health inequalities, the partnership and advances in care created during the pandemic must not be lost," Steele commented.

Steele succeeds Ashley Diaz-Granados, who assumes a senior role within Lilly USA leading the company’s Immunology division.